Back to Search
Start Over
Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
- Source :
- British Journal of Cancer; 9/15/2003, Vol. 89 Issue 6, p1008-1012, 5p
- Publication Year :
- 2003
-
Abstract
- A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Between June 1998 and August 2001, 50 patients were registered in this phase II study. Cisplatin (20 mg m(-2)) and ifosfamide (1.5 g m(-2)) were administered on days 1-4 and irinotecan (60 mg m(-2)) was given on days 1, 8, and 15, respectively. This regimen was repeated every 4 weeks. rhG-CSF was administered subcutaneously at a dose of 50 microg m(-2) on days 5-18 except on the days of irinotecan treatment. In total, 49 patients were assessable for toxicity and response and 50 for survival. In all, 33, patients (67.3%; 95% confidence interval 57.4-77.2%) achieved an objective response. The median response duration was 192 days and the median time to progression for 49 patients was 170 days. The median survival time was 540 days with 1- and 2-year survival rates of 63.5 and 30.7%, respectively. Grade 3 or 4 neutropenia and thrombocytopenia developed in 63.3 and 38.8% of the patients, respectively. In conclusion, the combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for the treatment of stage IIIB or IV NSCLC with acceptable toxicities. [ABSTRACT FROM AUTHOR]
- Subjects :
- GRANULOCYTES
LUNG cancer treatment
CISPLATIN
TOXICITY testing
CANCER chemotherapy
GRANULOCYTE-colony stimulating factor
ADENOCARCINOMA
ANTINEOPLASTIC agents
CAMPTOTHECIN
CANCER
CLINICAL trials
COMPARATIVE studies
DOSE-effect relationship in pharmacology
LUNG cancer
LUNG tumors
RESEARCH methodology
MEDICAL cooperation
RECOMBINANT proteins
RESEARCH
SQUAMOUS cell carcinoma
SURVIVAL
TUMOR classification
EVALUATION research
IFOSFAMIDE
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 00070920
- Volume :
- 89
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- British Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 10800472
- Full Text :
- https://doi.org/10.1038/sj.bjc.6601230